ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 083,71
-1,48%
DAX
18 691,32
0,05%
Brent Oil
81,225
-0,37%
Bitcoin
67 010,76
-3,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Precigen Inc (PGEN)

  7. Precigen Inc (PGEN) Actualités

PGEN

Precigen (PGEN)

Precigen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PGEN
DateHeureSourceTitreSymboleSociété
14/05/202423h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PGENPrecigen Inc
14/05/202423h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PGENPrecigen Inc
14/05/202422h05PR Newswire (US)Precigen Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
08/05/202422h05PR Newswire (US)Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202416h20PR Newswire (US)Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202415h00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:PGENPrecigen Inc
28/03/202421h05PR Newswire (US)Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thNASDAQ:PGENPrecigen Inc
19/03/202421h05PR Newswire (US)Precigen Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:PGENPrecigen Inc
12/03/202421h05PR Newswire (US)Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisNASDAQ:PGENPrecigen Inc
05/03/202422h05PR Newswire (US)Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19thNASDAQ:PGENPrecigen Inc
27/02/202419h48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PGENPrecigen Inc
14/02/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PGENPrecigen Inc
06/02/202422h05PR Newswire (US)Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:PGENPrecigen Inc
18/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PGENPrecigen Inc
16/01/202414h05PR Newswire (US)Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionNASDAQ:PGENPrecigen Inc
08/01/202414h30PR Newswire (US)Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PGENPrecigen Inc
29/12/202323h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PGENPrecigen Inc
18/12/202322h05PR Newswire (US)Precigen to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PGENPrecigen Inc
29/11/202322h05PR Newswire (US)Precigen to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:PGENPrecigen Inc
09/11/202322h55PR Newswire (US)Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical ProgramsNASDAQ:PGENPrecigen Inc
07/11/202322h05PR Newswire (US)Precigen to Participate in the Stifel 2023 Healthcare ConferenceNASDAQ:PGENPrecigen Inc
19/09/202322h05PR Newswire (US)Precigen to Participate in Upcoming Leading Investor and Industry ConferencesNASDAQ:PGENPrecigen Inc
26/08/202301h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PGENPrecigen Inc
09/08/202314h00PR Newswire (US)Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025NASDAQ:PGENPrecigen Inc
09/08/202313h05PR Newswire (US)Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated ApprovalNASDAQ:PGENPrecigen Inc
03/08/202322h05PR Newswire (US)Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9thNASDAQ:PGENPrecigen Inc
06/07/202323h09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PGENPrecigen Inc
20/06/202314h21Dow Jones NewsPrecigen Gets FDA Breakthrough Therapy Designation for AdenoVerseNASDAQ:PGENPrecigen Inc
20/06/202313h30PR Newswire (US)Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisNASDAQ:PGENPrecigen Inc
 Showing the most relevant articles for your search:NASDAQ:PGEN

Dernières Valeurs Consultées

BIT
1COST
Costco Wholesale
NASDAQ
AAYFHXX
Bofa Finance Llc Autocal...
NASDAQ
ABABFXX
Hsbc Bank Usa Na Capped ...
BIT
NSCIT5427876
SIT Societa Italiana Tra...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés